These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

703 related articles for article (PubMed ID: 27131792)

  • 1. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation.
    Yoshimura A; Iriki Y; Ichiki H; Oketani N; Okui H; Maenosono R; Namino F; Miyata M; Ohishi M
    J Cardiol; 2017 Jan; 69(1):228-235. PubMed ID: 27131792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.
    Kuwahara T; Abe M; Yamaki M; Fujieda H; Abe Y; Hashimoto K; Ishiba M; Sakai H; Hishikari K; Takigawa M; Okubo K; Takagi K; Tanaka Y; Nakajima J; Takahashi A
    J Cardiovasc Electrophysiol; 2016 May; 27(5):549-54. PubMed ID: 26766541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apixaban, rivaroxaban, and dabigatran use in patients undergoing catheter ablation for atrial fibrillation using the second-generation cryoballoon.
    Tscholl V; Lsharaf AK; Lin T; Bellmann B; Nagel P; Lenz K; Landmesser U; Roser M; Rillig A
    Clin Cardiol; 2017 Nov; 40(11):1095-1099. PubMed ID: 28846806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.
    Armbruster HL; Lindsley JP; Moranville MP; Habibi M; Khurram IM; Spragg DD; Berger RD; Calkins H; Marine JE
    Ann Pharmacother; 2015 Mar; 49(3):278-84. PubMed ID: 25515868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 9. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter study.
    Di Biase L; Lakkireddy D; Trivedi C; Deneke T; Martinek M; Mohanty S; Mohanty P; Prakash S; Bai R; Reddy M; Gianni C; Horton R; Bailey S; Sigmund E; Derndorfer M; Schade A; Mueller P; Szoelloes A; Sanchez J; Al-Ahmad A; Hranitzky P; Gallinghouse GJ; Hongo RH; Beheiry S; Pürerfellner H; Burkhardt JD; Natale A
    Heart Rhythm; 2015 Jun; 12(6):1162-8. PubMed ID: 25728754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation.
    Chan YH; See LC; Tu HT; Yeh YH; Chang SH; Wu LS; Lee HF; Wang CL; Kuo CF; Kuo CT
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29622587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
    Halvorsen S; Ghanima W; Fride Tvete I; Hoxmark C; Falck P; Solli O; Jonasson C
    Eur Heart J Cardiovasc Pharmacother; 2017 Jan; 3(1):28-36. PubMed ID: 27680880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study.
    Yu HT; Shim J; Park J; Kim TH; Uhm JS; Kim JY; Joung B; Lee MH; Kim YH; Pak HN
    Eur Heart J; 2019 May; 40(19):1531-1537. PubMed ID: 30590600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with direct oral anticoagulants or warfarin and the risk for incident diabetes among patients with atrial fibrillation: a population-based cohort study.
    Cheung CL; Sing CW; Lau WCY; Li GHY; Lip GYH; Tan KCB; Cheung BMY; Chan EWY; Wong ICK
    Cardiovasc Diabetol; 2021 Mar; 20(1):71. PubMed ID: 33766030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The incidence of asymptomatic cerebral microthromboembolism after atrial fibrillation ablation: comparison of warfarin and dabigatran.
    Ichiki H; Oketani N; Ishida S; Iriki Y; Okui H; Maenosono R; Namino F; Ninomiya Y; Miyata M; Hamasaki S; Tei C
    Pacing Clin Electrophysiol; 2013 Nov; 36(11):1328-35. PubMed ID: 23952291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU Trial.
    Reynolds MR; Allison JS; Natale A; Weisberg IL; Ellenbogen KA; Richards M; Hsieh WH; Sutherland J; Cannon CP
    JACC Clin Electrophysiol; 2018 May; 4(5):580-588. PubMed ID: 29798783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in atrial fibrillation: a nationwide cohort study.
    Rutherford OW; Jonasson C; Ghanima W; Söderdahl F; Halvorsen S
    Eur Heart J Cardiovasc Pharmacother; 2020 Apr; 6(2):75-85. PubMed ID: 31942972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA; Shrader P; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Hylek E; Kowey PR; Mahaffey KW; O'Brien EC; Singer DE; Peterson ED; Piccini JP;
    Am Heart J; 2017 Jul; 189():40-47. PubMed ID: 28625380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation.
    Nagao T; Inden Y; Shimano M; Fujita M; Yanagisawa S; Kato H; Ishikawa S; Miyoshi A; Okumura S; Ohguchi S; Yamamoto T; Yoshida N; Hirai M; Murohara T
    Pacing Clin Electrophysiol; 2015 Feb; 38(2):155-63. PubMed ID: 25487164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
    Hernandez I; Zhang Y; Saba S
    Am J Cardiol; 2017 Nov; 120(10):1813-1819. PubMed ID: 28864318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation.
    Okishige K; Nakamura T; Aoyagi H; Kawaguchi N; Yamashita M; Kurabayashi M; Suzuki H; Asano M; Shimura T; Yamauchi Y; Sasano T; Hirao K
    J Cardiol; 2017 Jan; 69(1):11-15. PubMed ID: 27160710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.